Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "GE"

8354 News Found

argenx advances clinical development of agonist antibody for myasthenic syndromes
News | July 04, 2025

argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept


Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability
News | July 03, 2025

Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability

InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services


Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel
Drug Approval | July 02, 2025

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Gel

Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery


Indegene identified as leader in ISG's Provider Lens for life sciences digital services
News | July 01, 2025

Indegene identified as leader in ISG's Provider Lens for life sciences digital services

ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems


Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Biotech | June 26, 2025

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability


Philogen withdraws marketing authorization application for Nidlegy in EU
News | June 26, 2025

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls


AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study
Clinical Trials | June 21, 2025

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month


Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Clinical Trials | June 21, 2025

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx


Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia
News | June 21, 2025

Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia

BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population